MAUDE Adverse Event Report: W. L. GORE & ASSOCIATES, INC. GORE VIABAHN ENDOPROSTHESIS WITH HEPARIN BIOACTIVE SURFACE; SYSTEM, ENDO GRAFT, ARTERIOVENOUS DIALYSIS ACCESS CIRCUIT STENOSIS TREATMENT

Model Number VBJR081002A

Device Problem Detachment of Device or Device Component (2907)

Patient Problem Foreign Body In Patient (2687)

Event Date 03/24/2021

Event Type  malfunction  

Manufacturer Narrative

Cbas® heparin surface incorporates cbas-heparin manufactured from heparin sodium api, which is covalently bound to the device surface and is essentially non-eluting.Review of device manufacturing record history confirmed device met pre-release specifications.The device remains implanted; therefore, direct product analysis was not possible.Instructions for use for gore® viabahn® endoprosthesis with heparin bioactive surface state: inspection prior to use; prior to using the gore® viabahn® endoprosthesis, all materials and equipment to be used for the procedure should be carefully examined for bends, kinks, or other damage.Do not use the gore® viabahn® endoprosthesis if the sterile package is compromised or the gore® viabahn® endoprosthesis is damaged.

Event Description

The following was reported to gore: on (b)(6) 2021, a diabetic patient underwent treatment due to an av fistula in the left upper arm.During the procedure, a 7fr 10cm terumo sheath was used to advance an 8 x 10 gore® viabahn® endoprosthesis with heparin bioactive surface (viabahn device) over an.018 v18 wire.As reported, the physician noted there was a kink at the transition area of the delivery catheter prior to device insertion.However, procedure continued and as device was being delivered to target treatment area, the delivery catheter was pulled back slightly through the sheath.At this time, the distal tip broke off the catheter.A new device was used to pin the distal tip against the vessel wall.The viabahn device was then deployed at other than the intended location.A new gore® viabahn® endoprosthesis with heparin bioactive surface was able to be advanced to treatment area.Device was deployed and procedure ended with good results.The patient was not adversely impacted.

Manufacturer Narrative

No physical evaluation could be conducted because the device was not returned to gore.Physical evaluation would allow confirmation on the separated device component(s) as described in the complaint as well as investigation of cause.Additional information about the procedure was requested, but no further detail was provided.The manufacturing records were reviewed, and the device lot met all pre-release specifications.This investigation confirms the reported distal tip separation, device components remaining in patient, and a kink in the catheter based on the reported complaint.The cause of the reported distal tip separation, device components remaining in patient, and the kink could not be confirmed.G4: pma/510k number was corrected.

• Brand Name: GORE VIABAHN ENDOPROSTHESIS WITH HEPARIN BIOACTIVE SURFACE
• Type of Device: SYSTEM, ENDO GRAFT, ARTERIOVENOUS DIALYSIS ACCESS CIRCUIT STENOSIS TREATMENT
• Manufacturer (Section D): W. L. GORE & ASSOCIATES, INC.; 1505 n. fourth street; flagstaff AZ 86004
• MDR Report Key: 11672192
• MDR Text Key: 249983738
• Report Number: 2017233-2021-01865
• Device Sequence Number: 1
• Product Code: PFV
• UDI-Device Identifier: 00733132623822
• UDI-Public: 00733132623822
• Combination Product (y/n): Y
• PMA/PMN Number: P130006
• Number of Events Reported: 1
• Summary Report (Y/N): N
• Report Source: Manufacturer
• Source Type: company representative,user f
• Type of Report: Initial,Followup
• Report Date: 08/10/2021

1 Device was Involved in the Event

1 Patient was Involved in the Event

• Is this an Adverse Event Report?: No
• Is this a Product Problem Report?: Yes
• Device Operator: Health Professional
• Device Expiration Date: 05/03/2023
• Device Model Number: VBJR081002A
• Device Catalogue Number: VBJR081002A
• Was Device Available for Evaluation?: No
• Initial Date Manufacturer Received: 03/24/2021
• Initial Date FDA Received: 04/15/2021
• Supplement Dates Manufacturer Received: 03/24/2021
• Supplement Dates FDA Received: 08/10/2021
• Patient Sequence Number: 1
• Patient Age: 56 YR
• Patient Weight: 78